Incretin Atlas › Trials › ELAD
ELAD
Liraglutide · Mild cognitive impairment + T2D
Design
- Molecule(s)
- Liraglutide
- Population
- Mild cognitive impairment + T2D
- Participants
- 396
- Duration
- 48 weeks
Outcomes in the indication
ELAD Liraglutide · Mild cognitive impairment + T2D · 48 weeks · n = 396 congress
MCI reversal 49.5 % vs 20.4 % on linagliptin (EASD 2026)
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline week 52 | — | — | −0.2 (−0.4 to +0.1) FDG-PET SUV | verified |
Verbatim quotes (1)
- Cerebral glucose metabolism (FDG-PET SUV, composite hippocampus/medial temporal lobe/posterior cingulate), change from baseline
The primary outcome showed no significant differences in cerebral glucose metabolism (difference = -0.17; 95% confidence interval: -0.39 to 0.06; P = 0.14) between the two groups.
Primary sources
- Zhou Zhang et al. Liraglutide and empagliflozin vs linagliptin on reversion of mild cognitive impairment in type 2 diabetes (LIGHT-MCI): a multicentre, randomised clinical trial. Abstract 140. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: OP 24 Protecting the brain]
- Edison P, Femminella GD, Ritchie C, Nowell J, Holmes C, Walker Z, et al. Liraglutide in mild to moderate Alzheimer's disease: a phase 2b clinical trial. Nat Med. 2026;32(1):353-361. PMID: 41326666.
How to cite this page
Medical Adviser's Group. Incretin Atlas: ELAD. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/elad/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.